查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1847875

肺炎链球菌检测市场：按检测类型、技术、应用、最终用户和分销管道划分 - 全球预测（2025-2032 年）

Pneumococcal Testing Market by Type Of Test, Technology, Application, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，肺炎球菌检测市场规模将达到 36.7 亿美元，复合年增长率为 9.25%。

主要市场统计数据
基准年 2024 18亿美元
预计年份：2025年 19.7亿美元
预测年份：2032年 36.7亿美元
复合年增长率 (%) 9.25%

这份策略性入门指南重点阐述了近期诊断技术的进步、临床需求和监测需求如何改变肺炎球菌检测和实验室工作的重点。

肺炎链球菌感染持续带来复杂的临床和公共卫生挑战，检测技术的进步在改善患者预后和指导预防策略方面发挥核心作用。如今，诊断工作需要在分子准确性、快速照护现场和以监测主导的公共卫生干预措施之间取得平衡。因此，实验室主任、临床微生物学家和公共卫生负责人必须在营运限制和监管要求的框架内权衡诊断的准确性、通量和及时性。

近年来，诊断创新已从纯培养鑑定转向更精细的分子和血清学方法，从而实现更早期、特异性的检测。这一发展与疫苗接种计划的扩展以及对血清型分布和抗生素抗药性监测需求的日益增长相吻合。同时，医疗卫生系统正在调整采购和检测管道，以适应多重检测平台和整合数据报告功能，从而更好地支援临床决策和流行病学追踪。

在此背景下，相关人员必须权衡近期临床效用与对基础设施、人才团队建设和资讯系统的长期投资。引入新型检测方法和分析技术需要谨慎的验证和实施策略，以在确保诊断品质的同时，最大限度地应对实际应用中的各种限制。如今在检测方法选择、实验室工作流程和监测方案设计方面所做的决定，将决定下一代肺炎链球菌控制措施及其降低发病率和死亡率的能力。

技术进步、数据系统整合和临床管道的改变将从根本上改变肺炎球菌检测和监测的方法。

由于技术的成熟、临床管道的转变以及公共卫生重点的不断变化，肺炎球菌检测领域正在发生显着变化。分子检测方法灵敏度更高，且能够在一次检测中检测多个靶标，正推动着检测方法从传统的仅培养法转变为分子检测方法的转变。同时，血清学方法也得到了改进，能够快速检测抗体和抗原，从而可以更迅速地评估免疫状态和疫苗效力。

检测也日益与数位健康和​​实验室资讯系统融合，增强了临床机构与公共卫生部门之间的数据流动。这种融合支持对血清流行率和抗药性模式的即时监测，从而能够更快地做出公共卫生应对。此外，越来越多的就地检验选择正在扩大门诊病人和社区的检测管道，改变检体收集管道和诊断管理模式。

另一项重大转变是强调能够同时识别和表征病原体的多重检测和基因组学方法。这些方法有助于进行准确的流行病学追踪并为疫苗政策决策提供信息，同时也对实验室生物资讯学和数据管治提出了新的要求。因此，诊断试剂生产商、临床实验室和公共卫生机构之间的合作正在加速，战略伙伴关係在部署可扩展且可持续的检测解决方案方面发挥着日益重要的作用。

评估2025年关税如何改变了肺炎球菌诊断生态系统的筹资策略、供应链韧性和平台选择

2025年关税的实施对肺炎球菌检测用品和设备的采购、生产和分销动态产生了广泛影响。进口关税和贸易调整影响了试剂、设备和耗材的采购决策，促使许多相关人员重新评估其供应商组合和供应链韧性。因此，诊断试剂生产商和实验室网路正在调整其生产和库存策略，以维持检测服务的连续性。

在营运方面，各实验室面临是否优先使用现有平台，或是投资于受关税价格波动影响较小的替代技术的抉择。采购团队的因应措施包括：协商长期供应协议、拓展与当地经销商的关係，以及在某些情况下加速对国内生产能力的投资。这种转变也影响了前置作业时间和物流规划，各公司更重视双轨供应策略和缓衝库存，以降低供应中断的风险。

监管机构和负责人致力于在确保获得必要诊断服务的同时，兼顾成本控制目标。支付方和医院管理者加强了对检测使用情况的审查，以维持预算稳定，这影响了高成本检测平台的推广应用。同时，关税压力推动了供应链区域化，并促进了优先考虑供应安全和符合当地市场要求的伙伴关係模式的建立。综上所述，这些动态凸显了策略采购、灵活选择检测平台以及积极主动的供应链管治对于在不断变化的贸易环境下维持诊断能力的重要性。

深入的細項分析揭示了检测方式、赋能技术、临床应用、终端用户环境和分销模式将如何推动诊断技术的普及应用。

了解市场区隔对于制定产品开发、研发和实验室应用策略至关重要。从检测类型来看，市场涵盖培养法、分子检测和血清学工具。基于培养的检测方法仍适用于抗菌药物敏感性试验和确证鑑定，其分为自动化培养系统（可提高通量）和传统培养方法（在许多诊断流程中仍然必不可少）。分子检测的特点是数位PCR、多重PCR和即时PCR的兴起，这些技术能够实现快速且灵敏的检测，并可同时分析多个标靶。血清学方法包括酵素结合免疫吸附检测法（ELISA）和快速免疫检测测定，可用于免疫状态​​评估和疫苗反应监测。 ELISA平台通常用于详细的血清型和抗体谱分析，而快速免疫检测则用于分散式检测。

技术细分有助于更清楚地了解竞争格局和临床应用现状。 ELISA平台分为间接法和夹心法，分别适用于不同的抗原-抗体动态变化。免疫层析法包括斑点印迹法和侧向流动法，适用于快速筛检和照护现场。新一代定序平台，例如Illumina和Ion Torrent，可提供高解析度的血清型分布和基因组监测功能，从而更深入地了解病原体的演化。 PCR检测仍然是一项关键技术，其中数位PCR可提供绝对定量，即时PCR兼顾了速度和分析性能。

应用主导细分揭示了诊断效用在携带者筛检、诊断、监测和疫苗评估中的差异。带因者筛检区分鼻咽拭子和口咽拭子采样方法，而诊断应用涵盖社区型肺炎、脑膜炎和中耳炎等临床症候群。监测活动着重于抗生素抗药性监测和血清型分布，以指导公共卫生干预措施，而疫苗评估则着重于临床前实验室数据和上市后监测，以衡量疫苗的实际有效性。最终使用者细分则着重于检测的运作环境，从社区健康中心和门诊诊所到大型和小型医院、地方和州级公共卫生实验室以及国家和地区级参考实验室，每个机构都有不同的工作流程、法规和预算考量。最后，分销管道多种多样，包括线上直销入口网站或专业销售团队、经销商、区域或全国性经销商，以及包括电子商务产品和製造商入口网站在内的线上平台，从而创造了多种市场管道和服务模式，供应商必须优化这些管道和服务模式才能接触到各种各样的买家。

一项比较区域研究，旨在探讨政策架构、实验室能力和供应链策略如何影响全球肺炎链球菌检测市场。

区域动态对诊断部署、监管管道和投资重点有显着影响。在美洲，临床实验室和公共卫生机构优先考虑快速、高通量检测，以支援临床管理和广泛的监测需求。该地区的医疗卫生系统倾向于采用能够与电子健康记录和公共卫生报告基础设施整合的多重检测和分子检测平台，而支付方系统则更注重检测管道的成本效益和价值驱动。

欧洲、中东和非洲是一个异质性区域，其监管环境、报销模式和公共卫生重点差异巨大。在一些地区，先进的参考实验室和国家监测计画正利用次世代定序和基因组流行病学技术绘製血清型转变图谱，而资源匮乏的地区则更依赖照护现场血清学和层析法检测来扩大检测范围。跨境合作与能力建构仍是核心议题，相关人员日益重视资料标准的统一，以确保不同辖区之间监控结果的可比较性。

在亚太地区，诊断基础设施的成长和对本地製造的投资显而易见，各国政府和相关人员优先考虑试剂生产和仪器服务的本土化能力。该地区正迅速采用数位化工作流程和分散式检查模式，并成为公私合营的活跃平台，旨在扩大监测和疫苗评估计画的规模。各地区的供应链策略和监管互动都根据当地市场结构量身定制，这就要求供应商设计灵活的商业模式，既要考虑到这些区域差异，又要确保品质和合规性。

提供公司层面的实用讯息，包括平台策略、策略伙伴关係和营运支持，这些资讯将决定肺炎球菌诊断领域的成功。

这些企业级动态的核心在于平台多元化、策略伙伴关係以及商业模式与不断变化的实验室需求的契合。诊断试剂製造商正增加涵盖中心实验室设备、床边分析仪和耗材生态系统等产品线的投资，以确保持续收入并深化客户关係。同时，他们也更加关注能够实现多重检测、血清分型以及与数位彙报工具整合的检测方法，以支援监测和临床决策。

随着企业寻求提供能够减少实验室实施摩擦的端到端解决方案，检测开发人员、设备供应商和资讯系统提供者之间的伙伴关係日益普遍。同样，受託製造厂商和特殊试剂供应商在确保供应连续性方面发挥着至关重要的作用，尤其是在地缘政治或贸易政策变化导致采购不确定性时。市场竞争者也增加对监管管道和临床证据的投入，以支持更广泛的适应症，例如门诊应用和公共卫生监测。

实验室网路和参考实验室透过参与验证研究、通讯协定协调和外部品质评估专案发挥影响力，进而影响新检测方法的应用模式。那些能够提供强而有力的售后支援、快速回应的技术服务和便利的培训资源的公司，往往能在分散的市场环境中获得更深层的渗透。总体而言，最成功的公司会将技术差异化与务实的商业化策略相结合，以满足不同终端使用者的实际业务需求。

针对诊断和检测产业领导者的具体策略行动，旨在增强互通性、供应链韧性、证据产生和客製化商业化方法。

产业领导者应优先采取一系列切实可行的措施，以巩固市场地位并支持公共卫生目标。首先，投资于平台互通性和数据整合能力将有助于提高产品普及率，因为实验室越来越需要仪器、实验室资讯系统和公共卫生资料库之间的无缝连接。透过消除整合障碍，企业可以加快客户实现价值的速度，并加强长期合作关係。

其次，透过多元化采购、区域製造伙伴关係和可扩展的库存策略来增强供应链韧性，可以降低贸易中断和关税波动带来的风险。策略采购安排以及与客户前置作业时间和紧急时应对计画进行透明沟通，有助于增强信任和业务永续营运。第三，针对不同临床适应症、检体类型和人群产生检验产品性能的针对性证据，有助于获得更广泛的临床认可和监管灵活性。强大的上市后监测和真实世界性能数据也有助于产品迭代改进。

第四，根据终端用户需求客製化市场推广策略——例如针对社区诊所、大型医院系统、公共卫生实验室和参考实验室提供差异化产品和服务——可以提高市场渗透率。这包括提供模组化培训、远端支援和灵活的销售条款，以反映各个细分市场的采购偏好。最后，上市公司应积极与公共卫生相关人员和支付方沟通，使其诊断提案主张与政策重点和报销框架保持一致。这些综合措施有助于应对不确定性，同时持续创造临床和公共卫生价值。

调查方法，结合相关人员访谈、文献回顾和跨领域分析，旨在提供可操作的诊断和政策见解。

支持这些见解的研究采用了多模态方法，以确保研究的整体性和实用性。主要研究包括对实验室主任、临床微生物学家、采购人员和公共卫生官员进行结构化访谈和定性咨询，以了解当地的营运观点和决策标准。与这些相关人员的互动为平台选择、验证要求和供应链敏感性提供了详细的背景信息，有助于解读诊断和监测领域的新兴趋势。

我们的二次研究综合了公开的监管指南、技术白皮书以及关于肺炎球菌诊断、血清型流行病学和检测方法的同行评审文献。我们专注于同侪审查的检验研究和官方公共卫生通报，以确保我们的技术评估基于严谨的证据。在适当情况下，我们审查了公司揭露的资讯和产品技术规格，以比较不同平台的功能集和整合能力。

分析方法包括交叉细分映射，以识别临床需求与技术能力的交集；以及情境分析，以探讨供应链或专案变更可能导致的招募管道变化。品质保证措施包括利用多个独立资讯来源检验定性调查结果，并由临床专家进行迭代审查，以确保解读结果反映实际情况。这种混合调查方法产生了可靠且可操作的见解，可为采购决策、平台投资和专案参与指南。

最后总结指出，技术创新、供应链稳健性和公共卫生策略合作之间的相互作用有助于减轻肺炎链球菌感染。

最后，肺炎球菌检测领域正处于曲折点交汇融合。分子和定序技术正在释放新的诊断和监测途径，而血清学检测和照护现场方法则持续扩大分散环境下的检测覆盖范围。这些互补的方法为临床医生和公共卫生官员提供了更丰富的套件，但也要求我们更加重视互通性、检验和品质保证。

近期政策变化和贸易动态的累积效应，凸显了製定具有韧性的筹资策略和灵活商业模式的必要性。同时，各地法规和检测能力的差异，要求供应商提供灵活的部署方案，以适应当地的限制和优先事项。积极主动地整合资源、累积证据并确保供应的公共机构和实验室网络，将更有利于满足当前的临床需求和实现长期的公共卫生目标。

为了成功应对这一局面，透明的数据共用和切实可行的实施管道需要LED、製造商、实验室和公共卫生机构之间的密切合作。透过将技术创新与实际应用和相关人员的需求相结合，诊断产业可以为减轻肺炎链球菌感染负担和加强未来的监测系统做出实际贡献。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 整合多种分子检测方法以快速鑑定肺炎球菌血清型和共存呼吸道病原体
  • 在服务不足和资源匮乏地区扩大即时聚合酵素链锁反应检测肺炎链球菌的规模
  • 利用新一代定序技术对肺炎链球菌菌株多样性和抗生素抗药性谱进行高解析度监测
  • 开发自动化样本到结果平台，以加快医院和临床实验室的工作流程
  • 推出云端基础的数据分析和数位报告工具，用于即时监测肺炎链球菌感染爆发情况

第六章美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

第八章 按检测类型分類的肺炎链球菌检测市场

  • 文化
    • 自动培养
    • 传统文化
  • 分子
    • 数位PCR
    • 多重PCR
    • 即时PCR
  • 血清学
    • ELISA
    • 快速免疫检测

9. 按技术分類的肺炎链球菌检测市场

  • ELISA
    • 间接ELISA
    • 夹心ELISA
  • 层析法试验
    • 点印法
    • 横向流动化验
  • 下一代定序
    • Illumina平台
    • 离子洪流
  • PCR检测
    • 数位PCR
    • 多重PCR
    • 即时PCR

第十章 按应用分類的肺炎链球菌检测市场

  • 携带者筛检
    • 鼻咽筛检
    • 口咽筛检
  • 诊断
    • 社区型肺炎
    • 脑膜炎
    • 中耳炎
  • 监测
    • 抗生素抗药性监测
    • 血清型分布
  • 疫苗评估
    • 上市后监测
    • 临床前试验

第十一章 依最终用户分類的肺炎链球菌检测市场

  • 诊所
    • 社区健康中心
    • 门诊部
  • 医院
    • 大型医院
    • 小型医院
  • 公共卫生实验室
    • 当地公共卫生实验室
    • 州公共卫生实验室
  • 参考实验室
    • 国家参考实验室
    • 区域参考实验室

第十二章 肺炎链球菌检测市场（依通路划分）

  • 直销
    • 在线的
    • 专业销售团队
  • 经销商
    • 当地经销商
    • 全国经销商
  • 在线的
    • 电子商务平台
    • 製造商门户

第十三章 肺炎链球菌检测市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 肺炎链球菌检测市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国肺炎链球菌检测市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • F. Hoffmann-La Roche Ltd
    • Abbott Laboratories
    • Becton, Dickinson and Company
    • bioMerieux SA
    • Thermo Fisher Scientific Inc.
    • QIAGEN NV
    • Hologic, Inc.
    • Bio-Rad Laboratories, Inc.
    • Seegene Inc.
    • Meridian Bioscience Inc.
Product Code: MRR-4103B31E098A

The Pneumococcal Testing Market is projected to grow by USD 3.67 billion at a CAGR of 9.25% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.80 billion
Estimated Year [2025] USD 1.97 billion
Forecast Year [2032] USD 3.67 billion
CAGR (%) 9.25%

A strategic primer highlighting how recent diagnostic advances, clinical imperatives, and surveillance needs are reshaping pneumococcal testing and laboratory priorities

Pneumococcal disease continues to present a complex clinical and public health challenge, and advances in testing are central to improving patient outcomes and informing prevention strategies. Diagnostics now operate at the intersection of molecular precision, rapid point-of-care delivery, and surveillance-driven public health interventions. As a result, laboratory directors, clinical microbiologists, and public health officials must weigh diagnostic accuracy, throughput, and timeliness against operational constraints and regulatory expectations.

Over recent years, diagnostic innovation has shifted the emphasis from purely culture-based identification to more nuanced molecular and serological approaches that enable earlier and more specific detection. This evolution aligns with expanding vaccination programs and heightened surveillance needs for serotype distribution and antibiotic resistance. Simultaneously, healthcare systems are recalibrating procurement and laboratory pathways to accommodate multiplexed platforms and integrated data reporting capabilities that better support clinical decision-making and epidemiological tracking.

In this context, stakeholders must balance near-term clinical utility with longer-term investments in infrastructure, workforce training, and information systems. The introduction of novel assays and analytic technologies demands careful validation and adoption strategies that preserve diagnostic quality while optimizing for real-world constraints. Ultimately, the choices made today in test selection, laboratory workflow, and surveillance design will define the next generation of pneumococcal control measures and their capacity to reduce morbidity and mortality.

How converging technological advances, integrated data systems, and shifting clinical pathways are fundamentally transforming pneumococcal testing and surveillance approaches

The landscape of pneumococcal testing is undergoing transformative shifts driven by technological maturation, changing clinical pathways, and evolving public health priorities. Molecular approaches that offer heightened sensitivity and the ability to detect multiple targets in a single assay are fostering a move away from sole reliance on traditional culture methods. At the same time, serological techniques have been refined for faster antibody and antigen detection, enabling more rapid assessments of immune status and vaccine effectiveness.

Testing is also becoming more integrated with digital health and laboratory information systems, which enhances data flow between clinical settings and public health authorities. This integration supports real-time surveillance of serotype prevalence and resistance patterns, and it enables more rapid public health responses. Furthermore, the diversification of point-of-care testing options is widening access in outpatient and community settings, thereby altering specimen collection pathways and diagnostic stewardship models.

Another significant shift is the emphasis on multiplexing and genomic methods that allow simultaneous pathogen identification and characterization. These approaches facilitate precise epidemiological tracking and inform vaccine policy decisions, while also placing new demands on laboratory bioinformatics and data governance. As a consequence, collaborations across diagnostic manufacturers, clinical laboratories, and public health institutions are accelerating, and strategic partnerships are increasingly central to deploying scalable, sustainable testing solutions.

Assessment of how 2025 tariff measures have reshaped procurement strategies, supply chain resiliency, and platform selection across the pneumococcal diagnostics ecosystem

The introduction of tariffs in 2025 has had a multi-dimensional impact on the procurement, manufacturing, and distribution dynamics for pneumococcal testing supplies and equipment. Import duties and trade adjustments have influenced sourcing decisions for reagents, instruments, and consumables, prompting many stakeholders to reassess supplier portfolios and supply chain resiliency. In turn, diagnostic manufacturers and laboratory networks are recalibrating production and inventory strategies to maintain continuity of testing services.

Operationally, laboratories faced decisions about prioritizing existing platforms versus investing in alternative technologies that are less exposed to tariff-driven price volatility. Procurement teams responded by negotiating long-term supply agreements, expanding local distributor relationships, and in some cases accelerating investments in domestic production capacities. These shifts have also affected lead times and logistics planning, with organizations placing greater emphasis on dual-source strategies and buffer stock to mitigate disruptions.

Policy responses have been notable, with regulators and payers engaging to ensure access to essential diagnostics while balancing cost containment goals. Payers and hospital administrators intensified scrutiny of test utilization to preserve budgetary stability, which in turn influenced adoption timelines for higher-cost platforms. At the same time, tariff pressures catalyzed regionalization of supply chains, encouraging partnership models that prioritize supply security and compliance with local market requirements. Taken together, these dynamics underscore the importance of strategic procurement, flexible platform selection, and proactive supply chain governance in preserving diagnostic capacity under changing trade conditions.

In-depth segmentation analysis revealing how test modalities, enabling technologies, clinical applications, end-user settings, and distribution models collectively drive diagnostic adoption

Understanding segmentation is essential for aligning product development, market access, and laboratory adoption strategies. From a test-type perspective, the market spans culture based methods, molecular assays, and serological tools. Culture based testing remains relevant for antimicrobial susceptibility and confirmatory identification, and it is split across automated culture systems that improve throughput and conventional culture methods that remain indispensable in many diagnostic workflows. Molecular testing is characterized by the rise of digital PCR, multiplex PCR, and real time PCR modalities that deliver rapid, sensitive detection and enable simultaneous analysis of multiple targets. Serological approaches-encompassing enzyme-linked immunosorbent assays and rapid immunoassays-support immune status evaluation and vaccine response monitoring, with ELISA platforms commonly used for detailed serotype and antibody profiling while rapid immunoassays serve decentralized settings.

Technology segmentation further clarifies the competitive and clinical landscape. ELISA platforms are differentiated into indirect and sandwich formats that address diverse antigen-antibody dynamics, while immunochromatographic tests include dot blot and lateral flow assay formats suitable for rapid screening and point-of-care use. Next-generation sequencing platforms such as Illumina and Ion Torrent offer high-resolution serotype distribution and genomic surveillance capabilities, enabling deep insights into pathogen evolution. PCR assays remain a cornerstone technology with digital PCR offering absolute quantification, multiplex PCR enabling broadened target panels, and real time PCR providing a balance of speed and analytical performance.

Application-driven segmentation highlights how diagnostic utility varies across carrier screening, diagnosis, surveillance, and vaccine evaluation. Carrier screening practices differentiate nasopharyngeal and oropharyngeal sampling approaches, whereas diagnostic use spans clinical syndromes such as community-acquired pneumonia, meningitis, and otitis media. Surveillance activities focus on antibiotic resistance monitoring and serotype distribution to inform public health interventions, and vaccine evaluation relies on both preclinical trial data and postmarketing surveillance to measure real-world vaccine impact. End-user segmentation addresses the operational contexts in which tests are deployed, ranging from community health centers and outpatient clinics to large and small hospitals, local and state public health laboratories, and national and regional reference laboratories, each with distinct workflow, regulatory, and budget considerations. Finally, distribution channels vary across direct sales-whether via online direct portals or specialty sales teams-distributors operating at local and national scales, and online platforms that include ecommerce offerings and manufacturer portals, creating multiple go-to-market pathways and service models that suppliers must optimize to reach diverse buyers.

Comparative regional insights examining how policy frameworks, laboratory capacity, and supply chain strategies shape pneumococcal testing across global markets

Regional dynamics exert a major influence on diagnostic deployment, regulatory pathways, and investment priorities. In the Americas, clinical laboratories and public health agencies place emphasis on rapid, high-throughput testing to support both clinical management and broad surveillance needs. Health systems in this region tend to adopt multiplex and molecular platforms that integrate with electronic health records and public health reporting infrastructures, while payer systems drive consideration of cost-effectiveness and value-based testing pathways.

Europe, Middle East & Africa presents a heterogeneous landscape where regulatory frameworks, reimbursement models, and public health priorities vary significantly. In some territories, sophisticated reference laboratories and national surveillance programs leverage next-generation sequencing and genomic epidemiology to map serotype shifts, whereas in lower-resource settings there is greater reliance on point-of-care serological and immunochromatographic tests to expand access. Cross-border collaboration and capacity building remain central themes, and stakeholders increasingly prioritize harmonized data standards to enable comparable surveillance outputs across jurisdictions.

In the Asia-Pacific region, growth in diagnostic infrastructure and investments in local manufacturing are notable, with governments and private stakeholders emphasizing domestic capability for reagent production and instrument servicing. This region demonstrates rapid adoption of digital workflows and decentralized testing models, and it is an active arena for public-private collaborations aimed at scaling surveillance and vaccine evaluation programs. Across all regions, supply chain strategies and regulatory engagement are tailored to local market structures, and vendors must design flexible commercial models that account for these regional differences while ensuring quality and compliance.

Practical company-level intelligence showing how platform strategies, strategic partnerships, and operational support determine success in the pneumococcal diagnostics arena

Company-level dynamics center on platform diversification, strategic partnerships, and the alignment of commercial models with evolving laboratory needs. Diagnostic manufacturers are increasingly investing in product families that span central laboratory instruments, near-patient analyzers, and consumable ecosystems to secure recurring revenue and deepen customer relationships. This trend is accompanied by heightened focus on assays that enable multiplex detection, serotype differentiation, and integration with digital reporting tools that support surveillance and clinical decision support.

Partnerships between assay developers, instrument suppliers, and informatics providers are becoming more common as firms seek to offer end-to-end solutions that reduce implementation friction for laboratories. Similarly, contract manufacturing organizations and specialty reagent suppliers play an important role in ensuring supply continuity, particularly when geopolitical or trade policy changes introduce procurement uncertainty. Market competitors are also investing in regulatory pathways and clinical evidence generation to support broader indications, including use cases in outpatient settings and public health surveillance.

Laboratory networks and reference institutions exert influence through validation studies, protocol harmonization, and participation in external quality assessment programs, which in turn shape adoption patterns for new assays. Companies that demonstrate strong postmarket support, rapid technical service, and accessible training resources tend to achieve deeper penetration in decentralized settings. Overall, the most successful firms combine technological differentiation with pragmatic commercialization strategies that address the operational realities of diverse end users.

Concrete strategic actions for diagnostic and laboratory leaders to enhance interoperability, supply chain resilience, evidence generation, and tailored commercialization approaches

Industry leaders should prioritize a set of actionable measures to solidify market position and support public health objectives. First, investing in platform interoperability and data integration capabilities will improve adoption, as laboratories increasingly require seamless connectivity between instruments, laboratory information systems, and public health databases. By addressing integration barriers, companies can accelerate time-to-value for customers and strengthen long-term relationships.

Second, enhancing supply chain resilience through diversified sourcing, regional manufacturing partnerships, and scalable inventory strategies will reduce exposure to trade-related disruptions and tariff volatility. Strategic procurement arrangements and transparent communication with customers about lead times and contingency plans will bolster trust and operational continuity. Third, targeted evidence generation that validates performance across clinical syndromes, specimen types, and demographic populations will support broader clinical acceptance and regulatory flexibility. Robust postmarket surveillance and real-world performance data will also inform iterative product improvements.

Fourth, tailoring go-to-market approaches to end-user needs-differentiating offerings for community clinics, large hospital systems, public health labs, and reference laboratories-will improve market penetration. This includes offering modular training, remote support, and flexible commercial terms that reflect the purchasing realities of each segment. Finally, companies should engage proactively with public health stakeholders and payers to align diagnostic value propositions with policy priorities and reimbursement frameworks. These combined actions will help leaders navigate uncertainty while delivering durable clinical and public health value.

Comprehensive blended research methodology combining stakeholder interviews, literature synthesis, and cross-segmentation analysis to produce pragmatic diagnostic and policy insights

The research underpinning these insights combined a multi-modal approach to ensure comprehensiveness and practical relevance. Primary research included structured interviews and qualitative consultations with laboratory directors, clinical microbiologists, procurement leads, and public health officials to capture on-the-ground operational perspectives and decision criteria. These stakeholder engagements provided detailed context on platform selection, validation requirements, and supply chain sensitivities, and they informed the interpretation of emerging trends in diagnostics and surveillance.

Secondary research synthesized publicly available regulatory guidance, technical white papers, and peer-reviewed literature on pneumococcal diagnostics, serotype epidemiology, and testing methodologies. Emphasis was placed on peer-reviewed validation studies and official public health communications to ensure that technological assessments were grounded in rigorous evidence. Where appropriate, company disclosures and product technical specifications were reviewed to map feature sets and integration capabilities across competing platforms.

Analytical methods included cross-segmentation mapping to identify where clinical needs intersect with technological capabilities, and scenario analysis to explore how supply chain or policy shifts could alter adoption pathways. Quality assurance measures involved validation of qualitative findings with multiple independent sources and iterative review by clinical experts to ensure that interpretations reflected practical realities. This blended methodology supports robust, actionable insights that can guide procurement decisions, platform investments, and policy engagement.

Final synthesis emphasizing the interplay between technological innovation, supply chain robustness, and collaborative public health strategies to reduce pneumococcal disease burden

In closing, the pneumococcal testing environment is at an inflection point where technological capability, supply chain realities, and public health priorities converge. Molecular and sequencing technologies are unlocking new diagnostic and surveillance possibilities, while serological assays and point-of-care formats continue to expand access in decentralized settings. These complementary modalities create a richer toolkit for clinicians and public health authorities but also demand greater attention to interoperability, validation, and quality assurance.

The cumulative effect of recent policy changes and trade dynamics has reinforced the need for resilient procurement strategies and adaptable commercial models. At the same time, regional differences in regulatory and laboratory capacity require suppliers to offer flexible deployment options that account for local constraints and priorities. Companies and laboratory networks that proactively address integration, evidence generation, and supply security will be best positioned to support both immediate clinical needs and longer-term public health objectives.

Ultimately, successful navigation of this landscape depends on close collaboration across manufacturers, laboratories, and public health institutions, guided by transparent data sharing and pragmatic implementation pathways. By aligning technological innovation with operational realities and stakeholder needs, the diagnostics community can contribute meaningfully to reducing the burden of pneumococcal disease and strengthening surveillance systems for the future.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of multiplex molecular assays for rapid differentiation of pneumococcal serotypes and co-circulating respiratory pathogens
  • 5.2. Expansion of point-of-care polymerase chain reaction testing for pneumococcal detection in underserved and resource-limited settings
  • 5.3. Adoption of next-generation sequencing for high-resolution surveillance of pneumococcal strain diversity and antibiotic resistance profiles
  • 5.4. Development of automated sample-to-answer platforms to accelerate pneumococcal testing workflows in hospital and clinical laboratory settings
  • 5.5. Implementation of cloud-based data analytics and digital reporting tools for real-time monitoring of pneumococcal infection outbreaks

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pneumococcal Testing Market, by Type Of Test

  • 8.1. Culture Based
    • 8.1.1. Automated Culture
    • 8.1.2. Conventional Culture
  • 8.2. Molecular
    • 8.2.1. Digital PCR
    • 8.2.2. Multiplex PCR
    • 8.2.3. Real Time PCR
  • 8.3. Serological
    • 8.3.1. Elisa
    • 8.3.2. Rapid Immunoassay

9. Pneumococcal Testing Market, by Technology

  • 9.1. Elisa
    • 9.1.1. Indirect Elisa
    • 9.1.2. Sandwich Elisa
  • 9.2. Immunochromatographic Test
    • 9.2.1. Dot Blot
    • 9.2.2. Lateral Flow Assay
  • 9.3. Next-Generation Sequencing
    • 9.3.1. Illumina Platform
    • 9.3.2. Ion Torrent
  • 9.4. Pcr Assay
    • 9.4.1. Digital PCR
    • 9.4.2. Multiplex PCR
    • 9.4.3. Real Time PCR

10. Pneumococcal Testing Market, by Application

  • 10.1. Carrier Screening
    • 10.1.1. Nasopharyngeal Screening
    • 10.1.2. Oropharyngeal Screening
  • 10.2. Diagnosis
    • 10.2.1. Community Acquired Pneumonia
    • 10.2.2. Meningitis
    • 10.2.3. Otitis Media
  • 10.3. Surveillance
    • 10.3.1. Antibiotic Resistance Monitoring
    • 10.3.2. Serotype Distribution
  • 10.4. Vaccine Evaluation
    • 10.4.1. PostMarketing Surveillance
    • 10.4.2. PreClinical Trials

11. Pneumococcal Testing Market, by End User

  • 11.1. Clinics
    • 11.1.1. Community Health Centers
    • 11.1.2. Outpatient Clinics
  • 11.2. Hospitals
    • 11.2.1. Large Hospitals
    • 11.2.2. Small Hospitals
  • 11.3. Public Health Labs
    • 11.3.1. Local Public Health Labs
    • 11.3.2. State Public Health Labs
  • 11.4. Reference Labs
    • 11.4.1. National Reference Labs
    • 11.4.2. Regional Reference Labs

12. Pneumococcal Testing Market, by Distribution Channel

  • 12.1. Direct Sales
    • 12.1.1. Online Direct
    • 12.1.2. Specialty Sales Team
  • 12.2. Distributors
    • 12.2.1. Local Distributors
    • 12.2.2. National Distributors
  • 12.3. Online
    • 12.3.1. Ecommerce Platforms
    • 12.3.2. Manufacturer Portals

13. Pneumococcal Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Pneumococcal Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Pneumococcal Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. F. Hoffmann-La Roche Ltd
    • 16.3.2. Abbott Laboratories
    • 16.3.3. Becton, Dickinson and Company
    • 16.3.4. bioMerieux SA
    • 16.3.5. Thermo Fisher Scientific Inc.
    • 16.3.6. QIAGEN N.V.
    • 16.3.7. Hologic, Inc.
    • 16.3.8. Bio-Rad Laboratories, Inc.
    • 16.3.9. Seegene Inc.
    • 16.3.10. Meridian Bioscience Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS PNEUMOCOCCAL TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST PNEUMOCOCCAL TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC PNEUMOCOCCAL TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN PNEUMOCOCCAL TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC PNEUMOCOCCAL TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION PNEUMOCOCCAL TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS PNEUMOCOCCAL TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 PNEUMOCOCCAL TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO PNEUMOCOCCAL TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. PNEUMOCOCCAL TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. PNEUMOCOCCAL TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PNEUMOCOCCAL TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY AUTOMATED CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY AUTOMATED CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY AUTOMATED CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY AUTOMATED CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY AUTOMATED CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY AUTOMATED CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CONVENTIONAL CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CONVENTIONAL CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CONVENTIONAL CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CONVENTIONAL CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CONVENTIONAL CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CONVENTIONAL CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MULTIPLEX PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MULTIPLEX PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MULTIPLEX PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MULTIPLEX PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MULTIPLEX PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MULTIPLEX PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REAL TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROLOGICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROLOGICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROLOGICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROLOGICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROLOGICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROLOGICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY RAPID IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY RAPID IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY RAPID IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY RAPID IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY RAPID IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY RAPID IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY INDIRECT ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY INDIRECT ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY INDIRECT ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY INDIRECT ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY INDIRECT ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY INDIRECT ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SANDWICH ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SANDWICH ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SANDWICH ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SANDWICH ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SANDWICH ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SANDWICH ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DOT BLOT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DOT BLOT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DOT BLOT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DOT BLOT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DOT BLOT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DOT BLOT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ILLUMINA PLATFORM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ILLUMINA PLATFORM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ILLUMINA PLATFORM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ILLUMINA PLATFORM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ILLUMINA PLATFORM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ILLUMINA PLATFORM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ION TORRENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ION TORRENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ION TORRENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ION TORRENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ION TORRENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ION TORRENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PCR ASSAY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PCR ASSAY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PCR ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PCR ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PCR ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PCR ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PCR ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PCR ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MULTIPLEX PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MULTIPLEX PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MULTIPLEX PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MULTIPLEX PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MULTIPLEX PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MULTIPLEX PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REAL TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NASOPHARYNGEAL SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NASOPHARYNGEAL SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NASOPHARYNGEAL SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NASOPHARYNGEAL SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NASOPHARYNGEAL SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NASOPHARYNGEAL SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OROPHARYNGEAL SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OROPHARYNGEAL SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OROPHARYNGEAL SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OROPHARYNGEAL SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OROPHARYNGEAL SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OROPHARYNGEAL SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY COMMUNITY ACQUIRED PNEUMONIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY COMMUNITY ACQUIRED PNEUMONIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY COMMUNITY ACQUIRED PNEUMONIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY COMMUNITY ACQUIRED PNEUMONIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY COMMUNITY ACQUIRED PNEUMONIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY COMMUNITY ACQUIRED PNEUMONIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MENINGITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MENINGITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MENINGITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MENINGITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MENINGITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MENINGITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OTITIS MEDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OTITIS MEDIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OTITIS MEDIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OTITIS MEDIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OTITIS MEDIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OTITIS MEDIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ANTIBIOTIC RESISTANCE MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ANTIBIOTIC RESISTANCE MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ANTIBIOTIC RESISTANCE MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ANTIBIOTIC RESISTANCE MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ANTIBIOTIC RESISTANCE MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ANTIBIOTIC RESISTANCE MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROTYPE DISTRIBUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROTYPE DISTRIBUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROTYPE DISTRIBUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROTYPE DISTRIBUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROTYPE DISTRIBUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROTYPE DISTRIBUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY VACCINE EVALUATION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY VACCINE EVALUATION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY VACCINE EVALUATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY VACCINE EVALUATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY VACCINE EVALUATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY VACCINE EVALUATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY VACCINE EVALUATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY VACCINE EVALUATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY POSTMARKETING SURVEILLANCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY POSTMARKETING SURVEILLANCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY POSTMARKETING SURVEILLANCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY POSTMARKETING SURVEILLANCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY POSTMARKETING SURVEILLANCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY POSTMARKETING SURVEILLANCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PRECLINICAL TRIALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PRECLINICAL TRIALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PRECLINICAL TRIALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PRECLINICAL TRIALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PRECLINICAL TRIALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PRECLINICAL TRIALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LARGE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LARGE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LARGE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LARGE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LARGE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LARGE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SMALL HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SMALL HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SMALL HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SMALL HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SMALL HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SMALL HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PUBLIC HEALTH LABS, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PUBLIC HEALTH LABS, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PUBLIC HEALTH LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PUBLIC HEALTH LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PUBLIC HEALTH LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PUBLIC HEALTH LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PUBLIC HEALTH LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PUBLIC HEALTH LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LOCAL PUBLIC HEALTH LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LOCAL PUBLIC HEALTH LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LOCAL PUBLIC HEALTH LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LOCAL PUBLIC HEALTH LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LOCAL PUBLIC HEALTH LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LOCAL PUBLIC HEALTH LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY STATE PUBLIC HEALTH LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY STATE PUBLIC HEALTH LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY STATE PUBLIC HEALTH LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY STATE PUBLIC HEALTH LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 309. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY STATE PUBLIC HEALTH LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 310. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY STATE PUBLIC HEALTH LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 311. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REFERENCE LABS, 2018-2